Acute myeloid leukaemia (AML) is a blood cancer that can arise as a consequence of treatment for other cancers. AML is diagnosed in 2,200 adults each year and it is thought that up to 10% of these cases are treatment-related.
Leukaemia is often triggered by DNA mutations within white blood cells when part of one chromosome exchanges with part of another in a process called translocation. For these chromosome rearrangements to occur, their constituent DNA must be broken and then repaired incorrectly. These mutated cells then divide uncontrollably in the blood, crowding out healthy blood cells.
Up to a third of treatment-related cases of AML can be attributed to chromosome rearrangements caused by the interaction between anti-cancer drugs and an enzyme called ‘TOP2B’. This enzyme is critical in managing DNA movement within cells and many cancers including lymphoma, testicular, lung and prostate cancers are sensitive to drugs that block its activity.
In a paper published online in the journal Proceedings of the National Academy of Sciences, USA, the Newcastle scientists showed that while drugs designed to inhibit TOP2 can be highly effective in preventing the rapid division of cancer cells, in some cases these drugs also cause key regions of important chromosomes to be held close together in a manner that increases the likelihood that the leukaemia inducing translocations occur.
Professor Caroline Austin, who led the team at the Institute for Cell and Molecular Biosciences at Newcastle University, said: “We are working to understand more about how these DNA breaks and rearrangements are made. The hope is that we will now be able to find ways of altering drug treatments to block this process, preventing secondary cancers from developing.”
Professor Chris Bunce, Research Director at Leukaemia & Lymphoma Research, said: “Although thankfully relatively rare, diagnosis with a second cancer due to treatment is a devastating blow for patients. It is vital that we reform and improve standard chemotherapy drugs to not just make them more effective but also reduce side effects. This study represents a huge breakthrough. It is the first time that scientists have looked into what is going on in the cell nucleus and explained exactly what happens when treatment-related DNA mutations occur.”
For further information, please contact Henry Winter at Leukaemia & Lymphoma Research Press Office on 020 7269 9019, press mobile 07824 375880, or email: email@example.com
Notes to editors
The findings are published online in the Proceedings of the National Academy of Sciences, USA on 21 May 2012 under the title ‘A model for MLL translocations in therapy-related leukemia involving topoisomerase IIβ mediated DNA strand breaks and gene proximity’. Corresponding author is Professor Caroline A Austin of the Institute for Cellular and Molecular Biosciences, The Medical School, Newcastle University
Leukaemia & Lymphoma Research is dedicated to saving the lives of blood cancer patients through the promotion and assistance of research into causes, diagnosis and treatment. We are committed to advancing the interests of patients and increasing public understanding of blood cancers.
Around 30,000 people of all ages, from children and teenagers to adults are diagnosed with blood cancers like leukaemia, lymphoma and myeloma in the UK every year.
We receive no government funding and rely entirely on voluntary support. In the next five years we need to raise £120 million to continue our lifesaving work. Further information, including patient information booklets, is available from beatingbloodcancers.org.uk or on 020 7405 0101.
NEWCASTLE UNIVERSITY is a leading UK higher education institution with a reputation for international excellence built on the quality of teaching, research and work with the community and industry. The University is a member of the Russell Group of 20 leading UK universities that are committed to maintaining the very best research, an outstanding teaching and learning experience and unrivalled links with business and the public sector. The University is based in the city of Newcastle upon Tyne, in North East England.
Science Press Officer
Leukaemia & Lymphoma Research
t: 020 7504 2219
f: 020 7405 3139